Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06687759 · ClinicalTrials.gov registry record · Phase 1

A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)

A Phase 1 study of Healthy, sponsored by Merck Sharp & Dohme.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT06687759 is a Phase 1 study of Healthy that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 8 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06687759, a Phase 1 study of Healthy, has completed, sponsored by Merck Sharp & Dohme.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn what happens to MK-1084 in a healthy person's body over time and how it is cleared from the body.

Conditions Studied

Interventions

  • DRUG [14C]MK-1084

Study Locations (1)

Wisconsin

  • Fortea CRU Madison (Site 0001) - Madison

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2024-06-26
Est. Completion 2024-08-07
Phase Phase 1

Sponsor

Merck Sharp & Dohme

558 total trials

What the Registry Record Tells You About NCT06687759

The ClinicalTrials.gov registry entry for NCT06687759 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which [14C]MK-1084 is the first listed.

NCT06687759 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06687759 about?

NCT06687759 is a clinical study titled "A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)". The purpose of this study is to learn what happens to MK-1084 in a healthy person's body over time and how it is cleared from the body.

What is the current status of trial NCT06687759?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-06-26. Estimated completion is 2024-08-07.

What conditions does trial NCT06687759 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT06687759?

The interventions under investigation include: [14C]MK-1084 (DRUG).

Who is sponsoring clinical trial NCT06687759?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06687759 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.